Efficacy and safety of bubble CPAP in neonatal care in low and middle income countries: a systematic review.
Simone Martin, Trevor Duke, Peter Davis
https://pubmed.ncbi.nlm.nih.gov/25085942/Actively Recruiting
Led by Tina Slusher · Updated on 2025-06-08
70
Participants Needed
2
Research Sites
8 weeks
Total Duration
Breathing problems are a major cause of newborn death and illness worldwide, especially in countries with limited healthcare resources like Nigeria and Nepal. This research focuses on newborns with mild to moderate respiratory distress and aims to test the feasibility and safety of using a low-cost breathing support device called the Neovent, which provides nasal intermittent positive pressure ventilation NIPPV. The study seeks to show that healthcare providers in low-resource nurseries can use the Neovent effectively and safely, comparing it to the current standard, bubble continuous positive airway pressure CPAP. The goal is to see if the Neovent causes no more safety issues such as nasal irritation, nosebleeds, stomach problems, or air around the lungs than the existing CPAP treatment. Newborns who qualify will be placed on the Neovent device for 6 hours, during which healthcare providers will set up, operate, and monitor the device. The study will track how well the staff can manage the device and identify any safety concerns. The Neovent is a non-electric, low-cost device designed to deliver NIPPV, which helps breathing by providing alternating air pressure through small nasal tubes. This study will take place in hospitals in Nigeria and Nepal and involves 70 newborn infants. During the 6-hour monitoring period, researchers will record vital signs like oxygen saturation, respiratory rate, heart rate, and the Downes score to assess breathing distress. They will also check hourly for complications such as nasal injury, nosebleeds, abdominal swelling, and pneumothorax. Safety assessments will be verified by study physicians. The main outcome is to confirm proper setup and use of the Neovent by healthcare providers and to ensure the safety profile is comparable to existing treatments. Participation will last for the duration of the 6-hour observation period.
CONDITIONS
Feasibility of Using the Neovent in Low-Resource Settings
T
Tina M Slusher, MD
I
Ibukun Sonaike, MBBS, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tina Slusher
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 hours
Participants with mild to moderate respiratory distress will receive bubble Nasal Intermittent Positive Pressure Ventilation (NIPPV) using the Neovent device while healthcare providers set up, operate, and monitor the device for safety.
Continuous monitoring during treatment period
Duration - Up to 6 hours
Participants will be assessed hourly during and after treatment for safety concerns such as nasal septal injury, nosebleeds, abdominal distention, and pneumothorax, with verification by study physicians.
Hourly assessments for up to 6 hours
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Simone Martin, Trevor Duke, Peter Davis
https://pubmed.ncbi.nlm.nih.gov/25085942/Stephen C John, Mehak Garg, Mounika Muttineni...
https://pubmed.ncbi.nlm.nih.gov/38361002/Brigitte Lemyre, Matthew Laughon, Carl Bose...
https://pubmed.ncbi.nlm.nih.gov/27976361/Michael Tsapis, Cécile Mignot, Sandrine Katsahian...
https://pubmed.ncbi.nlm.nih.gov/22005824/V Bhandari
https://pubmed.ncbi.nlm.nih.gov/19847188/U Schönherr, M Küchle, A Händel...
https://pubmed.ncbi.nlm.nih.gov/2358265/Joy E Lawn, Simon Cousens, Jelka Zupan...
https://pubmed.ncbi.nlm.nih.gov/15752534/Stephen C John, Azmath Mohammed, Joseph T Church...
https://pubmed.ncbi.nlm.nih.gov/32357365/B Lemyre, P G Davis, A G de Paoli
https://pubmed.ncbi.nlm.nih.gov/11869635/Stephen C John, Anna V John, Albert W Moss...
https://pubmed.ncbi.nlm.nih.gov/32209707/Tina Slusher
Lead Sponsor